組織診断薬市場：製品（抗体、キット、スライド染色システム、組織処理システム）、技術（ISH、IHC、特殊染色）、疾患（乳がん、NSCLC、リンパ腫）、エンドユーザー（病院、研究所）別 - 2027年までの世界予測

Tissue Diagnostics Market by Product(Antibodies, Kits, Slide Staining System, Tissue Processing System), Technology(ISH, IHC, Special Staining), Disease(Breast Cancer, NSCLC, Lymphoma), End User (Hospitals, Research Laboratories) - Global Forecast to 2027

組織診断の世界市場は、年平均成長率6.6％で推移しており、2022年の53億ドルから2027年には73億ドルに達すると予測されています。この市場の拡大は、主に腫瘍性疾患の有病率の上昇だけでなく、腫瘍スクリーニング... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2022年7月1日	US$4,950 シングルユーザライセンスライセンス・価格情報注文方法はこちら	240	229	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

組織診断の世界市場は、年平均成長率6.6％で推移しており、2022年の53億ドルから2027年には73億ドルに達すると予測されています。この市場の拡大は、主に腫瘍性疾患の有病率の上昇だけでなく、腫瘍スクリーニングの高い需要に起因している、しかし、熟練した専門家の不足は、この市場の成長を阻害する可能性があるための課題の一つです。

"器具のスライドステインシステムは2022年から2027年にかけて7.4%のCAGRで成長すると予測される"

組織診断市場は製品により、組織診断用消耗品（抗体、キット、試薬、プローブ）と組織診断用機器（スライド染色システム、スキャナー、組織処理システム、その他機器）に分類されます。この市場の成長は、自動化のメリット、スライド染色システムの大容量化、マニュアルエラーの排除、組織検査室へのハイスループット染色能力の提供などの要因によって大きく左右されます。

"アジア太平洋地域は、予測期間中に最も高いCAGRを記録すると推定される。"

本レポートでは、組織診断薬市場を北米、欧州、アジア太平洋地域、その他の地域（RoW）の4つの主要な地域セグメントに区分しています。アジア太平洋地域の市場は、予測期間中に最も高い成長率を記録すると予測されます。この市場の成長は、主にこの地域の国々の経済成長、大規模な人口基盤、慢性疾患の有病率の上昇、生活水準の向上、質の高い医療に対する需要の高まり、医療支出の増加、政府の取り組みの増加、組織診断検査の使用に関する意識の高まりによってもたらされています。

供給側の一次面接の内訳（企業タイプ別、呼称別、地域別）。

- 企業タイプ別Tier1 (32%) , Tier2 (44%) , Tier3 (24%)

- 役職別Cレベル (30%)、ディレクターレベル (34%)、その他 (36%)

- 地域別北米（40％）、欧州（28％）、アジア太平洋（20％）、その他の地域（12％）。

レポート掲載企業一覧

- F. ホフマン・ラ・ロシュ社（スイス(スイス)
- ダナハーコーポレーション（米国）
- サーモフィッシャーサイエンティフィック社（米国）
- アボット社(米国)
- アジレント・テクノロジー株式会社（米国）
- Merck KGAA（ドイツ）
- さくらファインテックジャパン株式会社（日本）
- Abcam Plc.(イギリス)
- ベクトン・ディッキンソンアンドカンパニー（BD）（米国）
- バイオSB（米）
- バイオジェニックス（米国）
- セル・シグナル・テクノロジー社（米国）
- ヒストラインラボラトリーズ（イタリア）
- SLEE Medical GMBH(ドイツ)
- ホロジック・インク(米国)
- Jinhua YIDI Medical Appliance Co.Ltd.（中国）
- MEDITE MEDICAL GMBH（ドイツ）
- Cellpath Ltd（イギリス）
- アモス・サイエンティフィック・ピーティーワイ・リミテッド（オーストラリア）
- Dipath S.P.A(イタリア)
- KFBIO KONFOONG BIOINFORMATION TECH CO.
- LTD（中国）、Diagnostic BioSystems Inc.（米国）
- 3DHISTECH LTD（ハンガリー）
- RWD LIFE SCIENCE CO.(中国)
- Dakewe Biotech Co.(中国)

調査対象範囲
本レポートでは、組織診断薬市場を製品別、地域別に調査しています。また、市場成長に影響を与える要因（促進要因、阻害要因、機会、課題など）を分析しています。利害関係者向けに市場の機会や課題を評価し、市場リーダー向けに競争環境の詳細を提供しています。また、マイクロマーケットについて、その成長動向、展望、組織診断市場全体への貢献度に関して調査しています。本レポートでは、5つの主要地域に関して、市場セグメントの収益を予測しています。

レポート購入の理由
本レポートは、以下のポイントに関する洞察を提供しています。

- 市場の浸透。組織診断市場の上位25社が提供する組織診断製品に関する包括的な情報。組織診断薬市場を製品別、地域別に分析したレポートです。

- 市場の発展。有利な新興市場に関する包括的な情報。本レポートでは、主要な地域ごとの各種固定装置市場を分析しています。

- 市場の多様化。組織診断市場における未開拓の地域、最近の開発、投資に関する徹底的な情報。

- 競合の評価。組織診断薬市場における主要企業の市場シェアと戦略に関する詳細な評価

ページTOPに戻る

1 INTRODUCTION 29
1.1 STUDY OBJECTIVES 29
1.2 MARKET DEFINITION 29
1.2.1 INCLUSIONS & EXCLUSIONS 29
1.3 MARKET SCOPE 30
1.3.1 GEOGRAPHIC SCOPE 30
1.3.2 YEARS CONSIDERED 31
1.4 CURRENCY 31
1.5 LIMITATIONS 31
1.6 MARKET STAKEHOLDERS 32
1.7 SUMMARY OF CHANGES 32
2 RESEARCH METHODOLOGY 34
2.1 RESEARCH DATA 34
FIGURE 1 RESEARCH DESIGN 34
2.1.1 SECONDARY DATA 35
2.1.1.1 Secondary sources 35
2.1.2 PRIMARY DATA 36
FIGURE 2 PRIMARY SOURCES 36
2.1.2.1 Key data from primary sources 37
2.1.2.2 Key industry insights 38
2.1.2.3 Breakdown of primary interviews 38
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS 38
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 39
2.2 MARKET SIZE ESTIMATION 39
FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION: DANAHER CORPORATION 40
FIGURE 6 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 40
2.2.1 GROWTH FORECAST 41
FIGURE 7 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS 41
FIGURE 8 TOP-DOWN APPROACH 42
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 43
FIGURE 9 DATA TRIANGULATION METHODOLOGY 43
2.4 MARKET SHARE ANALYSIS 44
2.5 ASSUMPTIONS FOR THE STUDY 44
2.6 INDICATORS AND ASSUMPTIONS AND THEIR IMPACT ON THE STUDY 45
2.6.1 COVID-19-SPECIFIC ASSUMPTIONS 45

2.7 RISK ASSESSMENT 46
TABLE 1 RISK ASSESSMENT 46
3 EXECUTIVE SUMMARY 47
FIGURE 10 TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION) 47
FIGURE 11 TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION) 48
FIGURE 12 TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2022 VS. 2027 (USD MILLION) 48
FIGURE 13 TISSUE DIAGNOSTICS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 49
FIGURE 14 GEOGRAPHIC SNAPSHOT OF GLOBAL TISSUE DIAGNOSTICS MARKET 50
4 PREMIUM INSIGHTS 51
4.1 TISSUE DIAGNOSTICS MARKET OVERVIEW 51
FIGURE 15 RISING PREVALENCE OF CANCER TO DRIVE MARKET GROWTH 51
4.2 TISSUE DIAGNOSTICS MARKET, BY PRODUCT 51
FIGURE 16 EQUIPMENT IN TISSUE DIAGNOSTICS SEGMENT TO REGISTER HIGHEST CAGR DURING 2022-2027. 51
4.3 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY DISEASE & COUNTRY 52
FIGURE 17 GASTRIC CANCER SEGMENT TO DOMINATE ASIA PACIFIC MARKET IN 2022 52
4.4 GEOGRAPHIC SNAPSHOT OF TISSUE DIAGNOSTICS MARKET 53
FIGURE 18 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 53
5 MARKET OVERVIEW 54
5.1 INTRODUCTION 54
5.2 MARKET DYNAMICS 54
FIGURE 19 TISSUE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 54
5.2.1 DRIVERS 55
5.2.1.1 Rising prevalence of cancer 55
TABLE 2 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION) 55
TABLE 3 PROJECTED INCREASE IN GLOBAL NUMBER OF CANCER PATIENTS, 2015 VS. 2018 VS. 2035 56
5.2.1.2 Growing demand for digital pathology 56
5.2.1.3 Increasing healthcare expenditure 57
FIGURE 20 CURRENT HEALTH EXPENDITURE PER CAPITA 57
FIGURE 21 CURRENT HEALTH EXPENDITURE (% OF GDP) 58
5.2.1.4 Developing infrastructure for cancer diagnosis 58
5.2.1.5 Increasing availability of reimbursements 59
5.2.1.6 Growing private diagnostics centers globally 60
5.2.1.7 Rising geriatric population with subsequent growth in chronic and infectious diseases 60
FIGURE 22 ESTIMATED INCREASE IN CANCER INCIDENCE (IN MILLION) 61
FIGURE 23 ESTIMATED DEATHS OF CANCER (IN MILLION) 61
5.2.2 RESTRAINTS 61
5.2.2.1 High degree of consolidation 61
5.2.3 OPPORTUNITIES 62
5.2.3.1 Significant opportunities in BRICS countries 62
FIGURE 24 GROWTH IN CURRENT HEALTHCARE EXPENDITURE PER CAPITA IN BRICS COUNTRIES, 2012–2019 62
5.2.3.2 Growing demand for personalized medicines 63
FIGURE 25 GROWTH OF PERSONALIZED MEDICINES APPROVED BY FDA, 2015–2021 63
5.2.3.3 Increasing number of clinical trials pertaining to cancer drugs 63
FIGURE 26 NUMBER OF ARTICLES RELATED TO TISSUE DIAGNOSTICS PUBLISHED ON PUBMED (2011–2021) 64
5.2.3.4 Emerging economies to offer significant opportunities to companies 65
5.2.4 CHALLENGES 65
5.2.4.1 Lack of skilled professionals 65
TABLE 4 NUMBER OF PATHOLOGISTS PER 100,000 POPULATION, BY COUNTRY, 2018 65
5.2.4.2 Availability of refurbished products 66
5.2.4.3 Product failures and recalls 66
5.2.4.4 Stringent regulatory requirements 66
5.2.4.5 Lack of infrastructure and low awareness in middle and low income countries 66
5.2.5 TRENDS 67
5.2.5.1 Increasing number of reagent rental agreements 67
5.2.5.2 Increasing usage of AI in histopathology 67
5.3 COVID-19 IMPACT ON TISSUE DIAGNOSTICS MARKET 68
5.4 RANGES/SCENARIOS 69
5.4.1 TISSUE DIAGNOSTICS MARKET 69
FIGURE 27 PESSIMISTIC SCENARIO 69
FIGURE 28 OPTIMISTIC SCENARIO 69
FIGURE 29 REALISTIC SCENARIO 70
5.5 VALUE CHAIN ANALYSIS 71
FIGURE 30 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASE 71
5.6 SUPPLY CHAIN ANALYSIS 72
FIGURE 31 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES 72
5.7 TECHNOLOGY ANALYSIS 73
5.8 PORTER’S FIVE FORCES ANALYSIS 73
5.8.1 THREAT OF NEW ENTRANTS 74
5.8.2 INTENSITY OF COMPETITIVE RIVALRY 74
5.8.3 BARGAINING POWER OF BUYERS 74
5.8.4 BARGAINING POWER OF SUPPLIERS 74
5.8.5 THREAT OF SUBSTITUTES 74

5.9 KEY STAKEHOLDERS & BUYING CRITERIA 74
5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS 74
FIGURE 32 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 3 END USERS 74
TABLE 5 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 3 END USERS (%) 75
5.9.2 BUYING CRITERIA 75
FIGURE 33 KEY BUYING CRITERIA FOR TOP 3 END USERS 75
TABLE 6 KEY BUYING CRITERIA FOR TOP 3 END USERS 75
5.10 REGULATORY LANDSCAPE 76
TABLE 7 INDICATIVE LIST OF REGULATORY AUTHORITIES GOVERNING TISSUE DIAGNOSTICS MARKET 76
5.11 PATENT ANALYSIS 78
5.12 KEY CONFERENCES & EVENTS IN 2022-2023 79
TABLE 8 LIST OF CONFERENCES & EVENTS 79
5.13 PRICING ANALYSIS 79
TABLE 9 PRICE RANGE FOR TISSUE DIAGNOSTICS 79
5.14 TRADE ANALYSIS 80
TABLE 10 IMPORT DATA FOR MICROTOMES, PARTS, AND ACCESSORIES OF INSTRUMENTS AND APPARATUS FOR PHYSICAL OR CHEMICAL ANALYSIS, BY COUNTRY, 2016–2020 (USD MILLION) 80
TABLE 11 EXPORT DATA FOR MICROTOMES, PARTS, AND ACCESSORIES OF INSTRUMENTS AND APPARATUS FOR PHYSICAL OR CHEMICAL ANALYSIS, BY COUNTRY, 2016–2020 (USD MILLION) 81
5.15 ECOSYSTEM ANALYSIS 81
TABLE 12 ROLE IN ECOSYSTEM 82
FIGURE 34 KEY PLAYERS OPERATING IN TISSUE DIAGNOSTICS MARKET 82
5.16 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 83
6 TISSUE DIAGNOSTICS MARKET, BY PRODUCT 84
6.1 INTRODUCTION 85
TABLE 13 TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION) 85
6.2 CONSUMABLES 85
TABLE 14 TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2027 (USD MILLION) 86
TABLE 15 TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY REGION, 2019–2027 (USD MILLION) 86
6.2.1 ANTIBODIES 86
TABLE 16 TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY REGION, 2019–2027 (USD MILLION) 87
6.2.2 KITS 87
TABLE 17 TISSUE DIAGNOSTICS MARKET FOR KITS, BY REGION, 2019–2027 (USD MILLION) 88
6.2.3 REAGENTS 88
TABLE 18 TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY REGION, 2019–2027 (USD MILLION) 89
6.2.4 PROBES 89
TABLE 19 TISSUE DIAGNOSTICS MARKET FOR PROBES, BY REGION, 2019–2027 (USD MILLION) 89
6.3 INSTRUMENTS 90
TABLE 20 TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2027 (USD MILLION) 90
TABLE 21 TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2019–2027 (USD MILLION) 90
6.3.1 SLIDE-STAINING SYSTEMS 91
TABLE 22 TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY REGION, 2019–2027 (USD MILLION) 91
6.3.2 SCANNERS 91
TABLE 23 TISSUE DIAGNOSTICS MARKET FOR SCANNERS, BY REGION, 2019–2027 (USD MILLION) 92
6.3.3 TISSUE-PROCESSING SYSTEMS 92
TABLE 24 TISSUE DIAGNOSTICS MARKET FOR TISSUE-PROCESSING SYSTEMS, BY REGION, 2019–2027 (USD MILLION) 92
6.3.4 OTHER INSTRUMENTS 93
TABLE 25 TISSUE DIAGNOSTICS MARKET FOR OTHER INSTRUMENTS, BY REGION, 2019–2027 (USD MILLION) 93
7 TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY 94
7.1 INTRODUCTION 95
TABLE 26 TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION) 95
7.2 IMMUNOHISTOCHEMISTRY (IHC) 95
TABLE 27 TISSUE DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY REGION, 2019–2027 (USD MILLION) 96
7.3 IN SITU HYBRIDIZATION (ISH) 97
TABLE 28 TISSUE DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2019–2027 (USD MILLION) 98
7.4 DIGITAL PATHOLOGY & WORKFLOW MANAGEMENT 98
TABLE 29 TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY & WORKFLOW MANAGEMENT, BY REGION, 2019–2027 (USD MILLION) 99
7.5 SPECIAL STAINING 99
TABLE 30 TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINING, BY REGION, 2019–2027 (USD MILLION) 99
8 TISSUE DIAGNOSTICS MARKET, BY DISEASE 100
8.1 INTRODUCTION 101
TABLE 31 GLOBAL CANCER INCIDENCE, 2018 VS. 2025 101
FIGURE 35 ARTICLES PUBLISHED ON CANCER TISSUE DIAGNOSTICS, 2011–2021 102
TABLE 32 TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2019–2027 (USD MILLION) 102

8.2 BREAST CANCER 102
TABLE 33 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040 103
FIGURE 36 ARTICLES PUBLISHED ON BREAST CANCER TISSUE DIAGNOSTICS, 2011–2021 103
TABLE 34 TISSUE DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION, 2019–2027 (USD MILLION) 104
8.3 GASTRIC CANCER 104
TABLE 35 COLORECTAL CANCER INCIDENCE, BY REGION, 2020 VS. 2040 105
FIGURE 37 ARTICLES PUBLISHED ON GASTRIC CANCER TISSUE DIAGNOSTICS, 2011–2021 105
TABLE 36 TISSUE DIAGNOSTICS MARKET FOR GASTRIC CANCER, BY REGION, 2019–2027 (USD MILLION) 106
8.4 LYMPHOMA 106
TABLE 37 HODGKIN LYMPHOMA INCIDENCE, BY REGION, 2018 VS. 2025 106
TABLE 38 NON-HODGKIN LYMPHOMA INCIDENCE, BY REGION, 2018 VS. 2025 107
FIGURE 38 ARTICLES PUBLISHED ON LYMPHOMA TISSUE DIAGNOSTICS, 2011–2021 107
TABLE 39 TISSUE DIAGNOSTICS MARKET FOR LYMPHOMA, BY REGION, 2019–2027 (USD MILLION) 107
8.5 PROSTATE CANCER 108
TABLE 40 PROSTATE CANCER INCIDENCE, BY REGION, 2018 VS. 2025 108
FIGURE 39 ARTICLES PUBLISHED ON PROSTATE CANCER TISSUE DIAGNOSTICS, 2011–2021 108
TABLE 41 TISSUE DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY REGION, 2019–2027 (USD MILLION) 109
8.6 NON-SMALL CELL LUNG CANCER 109
TABLE 42 NON-SMALL CELL LUNG CANCER INCIDENCE, BY REGION, 2020 VS. 2040 109
FIGURE 40 ARTICLES PUBLISHED ON NON-SMALL CELL LUNG CANCER TISSUE DIAGNOSTICS, 2011–2021 110
TABLE 43 TISSUE DIAGNOSTICS MARKET FOR NON-SMALL CELL LUNG CANCER, BY REGION, 2019–2027 (USD MILLION) 110
8.7 OTHER DISEASES 111
TABLE 44 TISSUE DIAGNOSTICS MARKET FOR OTHER DISEASES, BY REGION, 2019–2027 (USD MILLION) 111
9 TISSUE DIAGNOSTICS MARKET, BY END USER 112
9.1 INTRODUCTION 113
TABLE 45 TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION) 113
9.2 HOSPITALS 113
TABLE 46 TISSUE DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2019–2027 (USD MILLION) 114
9.3 RESEARCH LABORATORIES 114
TABLE 47 TISSUE DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, BY REGION, 2019–2027 (USD MILLION) 114
9.4 PHARMACEUTICAL COMPANIES 115
TABLE 48 TISSUE DIAGNOSTICS MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2019–2027 (USD MILLION) 115
9.5 CONTRACT RESEARCH ORGANIZATIONS 115
TABLE 49 ONCOLOGY CONTRACT RESEARCH ORGANIZATIONS (CROS). 116
TABLE 50 TISSUE DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2019–2027 (USD MILLION) 116
9.6 OTHER END USERS 116
TABLE 51 TISSUE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2019–2027 (USD MILLION) 117
10 TISSUE DIAGNOSTICS MARKET, BY REGION 118
10.1 INTRODUCTION 119
TABLE 52 TISSUE DIAGNOSTICS MARKET, BY REGION, 2019–2027 (USD MILLION) 119
10.2 NORTH AMERICA 119
FIGURE 41 NORTH AMERICA: CANCER INCIDENCE & MORTALITY, 2012–2035 120
FIGURE 42 TISSUE DIAGNOSTICS MARKET IN NORTH AMERICA: SNAPSHOT 121
TABLE 53 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 2019–2027 (USD MILLION) 121
TABLE 54 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION) 122
TABLE 55 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2027 (USD MILLION) 122
TABLE 56 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2027 (USD MILLION) 122
TABLE 57 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2019–2027 (USD MILLION) 123
TABLE 58 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION) 123
TABLE 59 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION) 124
10.2.1 US 124
10.2.1.1 US to dominate country-level market for tissue diagnostics 124
TABLE 60 US CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 125
TABLE 61 US: KEY MACROINDICATORS 125
TABLE 62 LIST OF US FDA-APPROVED PRODUCTS RELATED TO TISSUE DIAGNOSTICS 126
TABLE 63 US: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION) 126
TABLE 64 US: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION) 126
TABLE 65 US: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION) 127
10.2.2 CANADA 127
10.2.2.1 High prevalence of cancer to support market growth 127
TABLE 66 CANADA CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 128
TABLE 67 CANADA: KEY MACROINDICATORS 128
TABLE 68 CANADA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION) 129
TABLE 69 CANADA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION) 129
TABLE 70 CANADA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION) 130
10.3 EUROPE 130
FIGURE 43 EUROPE: CANCER INCIDENCE & MORTALITY, 2012–2035 130
TABLE 71 EUROPE: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 2019–2027 (USD MILLION) 131
TABLE 72 EUROPE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION) 131
TABLE 73 EUROPE: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2027 (USD MILLION) 132
TABLE 74 EUROPE: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2027 (USD MILLION) 132
TABLE 75 EUROPE: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2019–2027 (USD MILLION) 132
TABLE 76 EUROPE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION) 133
TABLE 77 EUROPE: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION) 133
10.3.1 GERMANY 134
10.3.1.1 Availability of reimbursements for colorectal cancer screening to drive market growth 134
TABLE 78 GERMANY CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 134
TABLE 79 GERMANY: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION) 135
TABLE 80 GERMANY: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION) 135
TABLE 81 GERMANY: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION) 135
10.3.2 UK 136
10.3.2.1 Government initiatives to drive market growth 136
TABLE 82 UK: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION) 136
TABLE 83 UK: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION) 137
TABLE 84 UK: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION) 137
10.3.3 FRANCE 137
10.3.3.1 Increasing government funding for cancer diagnosis & prevention to support market growth 137
TABLE 85 FRANCE CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 138
TABLE 86 FRANCE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION) 138
TABLE 87 FRANCE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION) 139
TABLE 88 FRANCE: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION) 139
10.3.4 ITALY 139
10.3.4.1 High incidence of cancer and geriatric population to support market growth 139
TABLE 89 ITALY CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 140
TABLE 90 ITALY: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION) 140
TABLE 91 ITALY: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION) 141
TABLE 92 ITALY: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION) 141
10.3.5 SPAIN 141
10.3.5.1 High incidence of chronic diseases to drive market growth 141
TABLE 93 SPAIN CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 142
TABLE 94 SPAIN: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION) 142
TABLE 95 SPAIN: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION) 142
TABLE 96 SPAIN: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION) 143
10.3.6 REST OF EUROPE 143
TABLE 97 LUNG CANCER INCIDENCE IN KEY REST OF EUROPE COUNTRIES, 2020 VS. 2040 143
TABLE 98 LIVER CANCER INCIDENCE IN KEY REST OF EUROPE COUNTRIES, 2020 VS. 2040 144
TABLE 99 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION) 144
TABLE 100 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION) 145
TABLE 101 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION) 145
10.4 ASIA PACIFIC 145
FIGURE 44 ASIA PACIFIC: CANCER INCIDENCE & MORTALITY, 2012–2035 146
FIGURE 45 TISSUE DIAGNOSTICS MARKET IN ASIA PACIFIC: SNAPSHOT 147
TABLE 102 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 2019–2027 (USD MILLION) 147
TABLE 103 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION) 148
TABLE 104 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2027 (USD MILLION) 148
TABLE 105 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2027 (USD MILLION) 148
TABLE 106 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2019–2027 (USD MILLION) 149
TABLE 107 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION) 149
TABLE 108 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION) 150

10.4.1 CHINA 150
10.4.1.1 Increasing healthcare expenditure and funding to drive market growth 150
TABLE 109 CHINA CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 150
TABLE 110 CHINA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION) 151
TABLE 111 CHINA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION) 151
TABLE 112 CHINA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION) 152
10.4.2 JAPAN 152
10.4.2.1 Advanced healthcare infrastructure to support market growth 152
TABLE 113 JAPAN: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040 152
TABLE 114 JAPAN: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION) 153
TABLE 115 JAPAN: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION) 154
TABLE 116 JAPAN: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION) 154
10.4.3 INDIA 154
10.4.3.1 Expanding healthcare sector to drive market growth 154
TABLE 117 INDIA CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 155
TABLE 118 INDIA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION) 156
TABLE 119 INDIA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION) 156
TABLE 120 INDIA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION) 156
10.4.4 REST OF ASIA PACIFIC 157
TABLE 121 INCIDENCE OF CANCER IN REST OF ASIA PACIFIC 157
TABLE 122 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION) 158
TABLE 123 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION) 158
TABLE 124 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION) 159
10.5 REST OF THE WORLD 159
TABLE 125 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY REGION, 2019–2027 (USD MILLION) 159
TABLE 126 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION) 160
TABLE 127 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2027 (USD MILLION) 160
TABLE 128 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2027 (USD MILLION) 160
TABLE 129 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2019–2027 (USD MILLION) 161
TABLE 130 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION) 161
TABLE 131 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION) 162
10.5.1 LATIN AMERICA 162
10.5.1.1 Increasing number of cancer screening programs to support market growth 162
TABLE 132 KEY LATIN AMERICAN COUNTRIES LUNG CANCER INCIDENCE, 2018 VS. 2025 162
TABLE 133 KEY LATIN AMERICAN COUNTRIES LIVER CANCER INCIDENCE, 2018 VS. 2025 163
TABLE 134 KEY LATIN AMERICAN COUNTRIES BREAST CANCER INCIDENCE, 2018 VS. 2025 163
TABLE 135 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION) 164
TABLE 136 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION) 164
TABLE 137 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION) 165
10.5.2 MIDDLE EAST & AFRICA 165
10.5.2.1 Increasing incidence of cancer to support market growth 165
TABLE 138 AFRICA CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 165
TABLE 139 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION) 166
TABLE 140 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION) 166
TABLE 141 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION) 167
11 COMPETITIVE LANDSCAPE 168
11.1 OVERVIEW 168
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 168
TABLE 142 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN TISSUE DIAGNOSTICS MARKET 168
11.3 REVENUE SHARE ANALYSIS 169
FIGURE 46 REVENUE ANALYSIS OF KEY PLAYERS IN TISSUE DIAGNOSTICS MARKET 169
11.4 MARKET SHARE ANALYSIS 170
TABLE 143 TISSUE DIAGNOSTICS MARKET: DEGREE OF COMPETITION 170
11.5 COMPANY EVALUATION QUADRANT 171
11.5.1 STARS 171
11.5.2 EMERGING LEADERS 171
11.5.3 PERVASIVE PLAYERS 171
11.5.4 PARTICIPANTS 171
FIGURE 47 COMPANY EVALUATION QUADRANT: TISSUE DIAGNOSTICS MARKET 172

11.6 COMPANY EVALUATION QUADRANT FOR SMES/START-UPS 173
11.6.1 PROGRESSIVE COMPANIES 173
11.6.2 STARTING BLOCKS 173
11.6.3 RESPONSIVE COMPANIES 173
11.6.4 DYNAMIC COMPANIES 173
FIGURE 48 COMPANY EVALUATION MATRIX FOR SMES/START-UPS: TISSUE DIAGNOSTICS MARKET 174
11.7 COMPANY FOOTPRINT ANALYSIS 175
11.7.1 COMPANY FOOTPRINT 175
11.7.2 COMPANY REGIONAL FOOTPRINT 176
11.7.3 COMPANY PRODUCT FOOTPRINT 177
11.8 COMPETITIVE BENCHMARKING 178
TABLE 144 TISSUE DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES 178
11.9 COMPETITIVE SCENARIO 179
11.9.1 PRODUCT LAUNCHES/APPROVALS 179
TABLE 145 KEY PRODUCT LAUNCHES 179
11.9.2 DEALS 179
TABLE 146 KEY DEALS 179
11.9.3 OTHER DEVELOPMENTS 180
TABLE 147 KEY OTHER DEVELOPMENTS 180
12 COMPANY PROFILES 181
(Business Overview, Products Offered, Recent Developments, and MnM View)*
12.1 KEY PLAYERS 181
12.1.1 F. HOFFMANN-LA ROCHE LTD 181
TABLE 148 F. HOFFMANN-LA ROCHE LTD: BUSINESS OVERVIEW 181
FIGURE 49 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2021) 182
12.1.2 DANAHER CORPORATION 186
TABLE 149 DANAHER CORPORATION: BUSINESS OVERVIEW 186
FIGURE 50 DANAHER CORPORATION: COMPANY SNAPSHOT (2021) 187
12.1.3 THERMO FISHER SCIENTIFIC INC. 191
TABLE 150 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 191
FIGURE 51 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2021) 192
12.1.4 ABBOTT 195
TABLE 151 ABBOTT: BUSINESS OVERVIEW 195
FIGURE 52 ABBOTT.: COMPANY SNAPSHOT (2021) 196
12.1.5 AGILENT TECHNOLOGIES INC. 198
TABLE 152 AGILENT TECHNOLOGIES INC.: BUSINESS OVERVIEW 198
FIGURE 53 AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT (2021) 199

12.1.6 MERCK KGAA 201
TABLE 153 MERCK KGAA: BUSINESS OVERVIEW 201
FIGURE 54 MERCK KGAA COMPANY SNAPSHOT (2021) 202
12.1.7 SAKURA FINETEK JAPAN CO., LTD. 204
TABLE 154 SAKURA FINETEK JAPAN CO., LTD.: BUSINESS OVERVIEW 204
12.1.8 ABCAM PLC. 207
TABLE 155 ABCAM PLC.: BUSINESS OVERVIEW 207
FIGURE 55 ABCAM PLC. COMPANY SNAPSHOT (2021) 208
12.1.9 BECTON, DICKINSON AND COMPANY (BD) 210
TABLE 156 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 210
FIGURE 56 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021) 211
12.1.10 BIO SB 213
TABLE 157 BIO SB: BUSINESS OVERVIEW 213
12.1.11 BIOGENEX 215
TABLE 158 BIOGENEX.: BUSINESS OVERVIEW 215
12.1.12 CELL SIGNALING TECHNOLOGY, INC. 217
TABLE 159 CELL SIGNALING TECHNOLOGY, INC.: BUSINESS OVERVIEW 217
12.1.13 HISTO-LINE LABORATORIES 218
TABLE 160 HISTO-LINE LABORATORIES: BUSINESS OVERVIEW 218
12.1.14 SLEE MEDICAL GMBH 220
TABLE 161 SLEE MEDICAL GMBH.: BUSINESS OVERVIEW 220
12.1.15 AMOS SCIENTIFIC PTY LTD 222
TABLE 162 AMOS SCIENTIFIC PTY LTD: BUSINESS OVERVIEW 222
12.1.16 JINHUA YIDI MEDICAL APPLIANCE CO. LTD 224
TABLE 163 JINHUA YIDI MEDICAL APPLIANCE CO.LTD: BUSINESS OVERVIEW 224
12.1.17 MEDITE MEDICAL GMBH 226
TABLE 164 MEDITE MEDICAL GMBH: BUSINESS OVERVIEW 226
12.1.18 CELLPATH LTD 227
TABLE 165 CELLPATH LTD: BUSINESS OVERVIEW 227
12.1.19 HOLOGIC, INC 228
TABLE 166 HOLOGIC, INC: BUSINESS OVERVIEW 228
FIGURE 57 HOLOGIC, INC.: COMPANY SNAPSHOT (2021) 229
12.1.20 DIAPATH S.P.A. 231
TABLE 167 DIAPATH S.P.A.: BUSINESS OVERVIEW 231
12.1.21 KFBIO KONFOONG BIOINFORMATION TECH CO., LTD 233
TABLE 168 KFBIO KONFOONG BIOINFORMATION TECH CO., LTD: BUSINESS OVERVIEW 233
12.1.22 DIAGNOSTIC BIOSYSTEMS INC. 234
TABLE 169 DIAGNOSTIC BIOSYSTEMS INC.: BUSINESS OVERVIEW 234
12.1.23 3DHISTECH LTD. 235
TABLE 170 3DHISTECH LTD: BUSINESS OVERVIEW 235

12.1.24 RWD LIFE SCIENCE CO., LTD. 236
TABLE 171 RWD LIFE SCIENCE CO., LTD.: BUSINESS OVERVIEW 236
12.1.25 DAKEWEI BIOTECHNOLOGY CO., LTD. 237
TABLE 172 DAKEWEI BIOTECHNOLOGY CO., LTD.: BUSINESS OVERVIEW 237
* Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
13 APPENDIX 238
13.1 INDUSTRY INSIGHTS 238
13.2 DISCUSSION GUIDE 239
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 243
13.4 AVAILABLE CUSTOMIZATIONS 245
13.5 RELATED REPORTS 245
13.6 AUTHOR DETAILS 246

ページTOPに戻る

Table of Contents

Summary

The global Tissue Diagnostics market is growing at a CAGR of 6.6% during and it is expected to reach USD 7.3 billion by 2027 from USD 5.3 billion in 2022, during the forecast period. The expansion of this market is majorly due to rising prevalence of neoplastic cases as well as high demand of oncology screening, However, Lack of skilled professionals is one of the challenge for which may inhibit the growth of this market.

“The Slide-Staining Systems in instruments is projected to grow at CAGR of 7.4% from 2022 to 2027”

Based on the product, the tissue diagnostics market is classified into tissue diagnostics consumables (Antibodies, Kits, Reagents, Probes) and tissue diagnostics Instruments (Slide-staining Systems, Scanners, Tissue-processing Systems, Other Instruments). The growth of this market is majorly driven by the factors such as benefits of automation, the greater capacity of slide staining systems, and the elimination of manual errors, and delivering high throughput staining capabilities for histology laboratories.

“Asia Pacific is estimated to register the highest CAGR during the forecast period.”

In this report, the tissue diagnostics market is segmented into four major regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). The market in Asia Pacific is projected to register the highest growth rate during the forecast period. The growth in this market is primarily driven by the economic growth in the countries of this region, large population base, the rising prevalence of chronic diseases, the rising standard of living, growing demand for quality medical care, increasing healthcare spending, increasing government initiatives, and rising awareness regarding the use of tissue diagnostic tests

Breakdown of supply-side primary interviews, by company type, designation, and region:

• By Company Type: Tier 1 (32%) , Tier 2 (44%), and Tier 3 (24%)

• By Designation: C-level (30%), Director-level (34%), and Others (36%)

• By Region: North America (40%), Europe (28%), AsiaPacific (20%), and Rest of the World(12%)

List of Companies Profiled in the Report

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Danaher Corporation (US)
• Thermo Fisher Scientific, Inc (US)
• Abbott (US)
• Agilent Technologies Inc. (US)
• Merck KGAA (Germany)
• SAKURA FINETEK JAPAN CO., LTD (Japan)
• Abcam Plc. (UK)
• Becton, Dickinson and Company (BD) (US)
• Bio SB (US)
• Biogenix (US)
• Cell Signaling Technology, Inc (US)
• Histo-Line Laboratories (Italy)
• SLEE Medical GMBH (Germany)
• Hologic Inc. (US).
• Jinhua YIDI Medical Appliance Co. Ltd (China)
• MEDITE MEDICAL GMBH (Germany)
• Cellpath Ltd (UK)
• Amos scientific Pty Ltd (Australia)
• Dipath S.P.A (Italy)
• KFBIO KONFOONG BIOINFORMATION TECH CO
• LTD (China), Diagnostic BioSystems Inc. (US)
• 3DHISTECH LTD (Hungary)
• RWD LIFE SCIENCE CO., LTD. (China)
• Dakewe Biotech Co., Ltd. (China)

Research Coverage:
This report studies the tissue diagnostics market based on product, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total tissue diagnostics market. The report forecasts the revenue of the market segments with respect to five major regions.

Reasons to Buy the Report:
The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on tissue diagnostics products offered by the top 25 players in the tissue diagnostics market. The report analyzes the tissue diagnostics market by product, and region.

• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various securement devices across key geographic regions.

• Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the tissue diagnostics market

• Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the tissue diagnostics market

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（診断薬）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（cancer）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

組織診断薬市場：製品（抗体、キット、スライド染色システム、組織処理システム）、技術（ISH、IHC、特殊染色）、疾患（乳がん、NSCLC、リンパ腫）、エンドユーザー（病院、研究所）別 - 2027年までの世界予測

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（診断薬）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（cancer）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?